

Are your **MRI contrast agents** cost-effective?

Learn more about generic **Gadolinium-Based Contrast Agents**.



FRESENIUS
KABI

caring for life

AJNR

Cranial Computed Tomographic Abnormalities in Leptomeningeal Metastasis

Ya-Yen Lee, J. Peter Glass, Anne Geoffray and Sidney Wallace

AJNR Am J Neuroradiol 1984, 5 (5) 559-563

<http://www.ajnr.org/content/5/5/559>

This information is current as
of April 20, 2024.

Cranial Computed Tomographic Abnormalities in Leptomeningeal Metastasis

Ya-Yen Lee¹
 J. Peter Glass²
 Anne Geoffray¹
 Sidney Wallace¹

Sixty-four (57.6%) of 111 cancer patients with cerebrospinal fluid cytology positive for malignant cells had cranial computed tomographic (CT) scans within 2 weeks before or after a lumbar puncture. Twenty-two (34.3%) of the 64 had abnormal CT findings indicative of leptomeningeal metastasis: (1) sulcal-cisternal enhancement, (2) ependymal-subependymal enhancement, (3) widened irregular tentorial enhancement, or (4) communicating hydrocephalus. Thirteen (59.6%) of these 22 patients had associated parenchymal metastases. Recognition of leptomeningeal disease may alter the management of patients with parenchymal metastases. Communicating hydrocephalus in cancer patients should be considered to be related to leptomeningeal metastasis until proven otherwise.

Leptomeningeal metastasis is associated with a relatively poor prognosis. However, vigorous treatment with intrathecal chemotherapeutic agents and/or radiation therapy can improve symptoms and at times prolong survival [1]. The diagnosis of leptomeningeal metastasis by cranial computed tomography (CT) contributes to earlier treatment and sometimes alters the management of patients with parenchymal metastases. The findings and differential diagnosis of leptomeningeal metastasis are discussed from the evaluation of CT scans in 64 patients whose cerebrospinal fluid (CSF) cytologic examinations were positive for malignant cells.

Materials and Methods

During a 1 year period, 111 cancer patients at M. D. Anderson Hospital and Tumor Institute had a CSF cytology positive for malignant cells. The data were obtained from three major sources: cytopathology records; hematology records of CSF cell counts and differentials; and neurosurgical operative records of the placement of Ommaya reservoirs. The types of primary neoplasms are listed in table 1. Of the 111 patients, 44 (29.6%) had leukemia and 19 (16.2%) had lymphoma. The solid tumors included carcinoma of the breast in 21 (18.9%) patients and carcinoma of the lung in 11 (10%). Sixty-four (57.6%) of the 111 had CT scans within 2 weeks before or after a lumbar puncture.

CT studies were performed on GE CT/T 8800 or Siemens Somatom-2 or DR-3 scanners at 8 or 10 mm intervals using horizontal cuts from the base of the skull to the vertex. All examinations were done before and immediately after intravenous infusion of 300 ml of 30% meglumine diatrizoate (42.3 g iodine) over 10 min.

Results

Twenty-two (34.3%) of the 64 patients examined by CT had definite abnormalities that could be related to leptomeningeal metastasis, that is, sulcal-cisternal enhancement, ependymal-subependymal enhancement, widened irregular tentorial enhancement, or communicating hydrocephalus. All those studies with only suggestive or questionable findings were discarded.

Sixteen patients exhibited sulcal-cisternal enhancement that was localized in

This article appears in the September/October 1984 issue of *AJNR* and the November 1984 issue of *AJR*.

Received November 28, 1983; accepted after revision February 7, 1984.

¹ Department of Diagnostic Radiology, University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, 6723 Bertner Ave., Houston, TX 77030. Address reprint requests to Y.-Y. Lee.

² Section of Neurology, University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, TX 77030.

AJNR 5:559-563, September/October 1984
 0195-6108/84/0505-0559

© American Roentgen Ray Society

TABLE 1: Primary Neoplasms in Cancer Patients with CSF Cytology Positive for Malignant Cells

| Primary Neoplasm | No. of Patients with Positive CSF Cytology | No. of Cranial CT Studies | |
|---------------------|--|---------------------------|--|
| | | Total | Positive for Leptomeningeal Metastasis |
| Leukemia* | 44 | 19 | 3 |
| Lymphoma* | 18 | 12 | 2 |
| Breast | 21 | 17 | 7 |
| Lung | 11 | 7 | 4 |
| Multiple myeloma | 4 | 2 | 2 |
| Other tumors† | 7 | 3 | 1 |
| Pinealoblastoma | 1 | 1 | 1 |
| Medulloblastoma | 3 | 2 | 1 |
| Other brain tumors‡ | 2 | 1 | 1 |
| Total | 111 | 64 | 22 |

Note.—Cranial CT studies were performed within 2 weeks before or after the cerebrospinal fluid (CSF) examinations.

* Routine CSF cytology for all new patients staging and restaging.

† One retinoblastoma; one giant cell astrocytoma.

‡ One transitional cell carcinoma of the bladder; one neuroblastoma; one rhabdomyosarcoma; one undifferentiated carcinoma; two unknown primary; one Ewing sarcoma.

three and diffuse in 13 (fig. 1). There was ependymal-subependymal enhancement in three patients (fig. 2). Thickened irregular tentorial enhancement was seen in seven patients; it was localized in two and diffuse in five (fig. 3). Communicating hydrocephalus was noted in 13 patients (fig. 4).

Nine patients had one positive finding on CT: four with sulcal-cisternal enhancement, one with ependymal-subependymal enhancement, two with tentorial enhancement, and two with communicating hydrocephalus. Two or more CT findings related to leptomeningeal metastasis were seen in 13 patients, with sulcal-cisternal enhancement and communicating hydrocephalus in six as the most frequent combination (table 2).

Additional data collected revealed that 13 (59.6%) of the 22 patients with CT scans indicative of leptomeningeal metastasis also had parenchymal lesions; nine were metastatic and four were residual primary tumors.

Discussion

Leptomeningeal metastasis is defined as diffuse or widespread multifocal involvement of the subarachnoid space by metastatic tumor. The disease, also known as meningeal carcinomatosis or carcinomatous meningitis, has been discussed in the English-language literature since 1912 [2]. The incidence is variable, based largely on autopsy studies, and accounts for 8%–10% of all intracranial metastases [3]. There is presumptive evidence that this manifestation of cancer is increasing in frequency, particularly in lymphoma [4–6], breast carcinoma [7], and oat cell carcinoma of the lung [8]. This has occurred because of the availability of more effective systemic chemotherapeutic agents, which prolong survival, as well as the increased capacity of physicians to make the diagnosis of leptomeningeal involvement.

There are a number of proposed mechanisms for the spread of tumor to the leptomeninges [9]. A primary or metastatic parenchymal lesion is a frequently cited source of spread [10–




Fig. 1.—A and B, Localized abnormal leptomeningeal enhancement in left sylvian fissure and cortical sulci in adenocarcinoma of the lung with proven leptomeningeal metastasis. C and D, Diffuse sulcal enhancement with carcinoma of the breast. Obliteration of cortical sulci by leptomeningeal enhancement; associated communicating hydrocephalus.




Fig. 2.—Enhancing subependymal lesion in head of left caudate nucleus without surrounding edema in acute myelocytic leukemia with localized sulcal enhancement.

12]. However, the rupture of the pial surface by a parenchymal tumor is usually accompanied by a focal fibrous reaction that prevents the dissemination of exfoliated cells. Instead, rupture into the ventricular system is believed to be a more likely

Fig. 3.—**A**, Localized tentorial enhancement in malignant melanoma. **B** and **C**, Diffuse tentorial enhancement in carcinoma of the breast. Associated sulcal enhancement and ependymal-subependymal lesion in head of right caudate nucleus.





Fig. 4.—Symmetric ventricular dilatation of mild degree in 56-year-old patient with carcinoma of the breast. Obliteration of cortical sulci, consistent with communicating hydrocephalus, with diffuse leptomeningeal enhancement.

TABLE 2: Cranial CT Abnormalities in Leptomeningeal Metastases

| Abnormalities | No. of Patients |
|---|-----------------|
| Sulcal-cisternal enhancement | 4 |
| Ependymal-subependymal enhancement | 1 |
| Tentorial enhancement | 2 |
| Communicating hydrocephalus | 2 |
| Sulcal-cisternal and ependymal-subependymal enhancement | 1 |
| Sulcal-cisternal and tentorial enhancement | 1 |
| Sulcal-cisternal enhancement and communicating hydrocephalus | 1 |
| Tentorial enhancement and communicating hydrocephalus | 3 |
| Sulcal-cisternal and tentorial enhancement and communicating hydrocephalus | 3 |
| Sulcal-cisternal, tentorial, and ependymal-subependymal enhancement and communicating hydrocephalus | 1 |
| Total | 22 |

route of dissemination because it is not associated with a surrounding tissue reaction [13]. The choroid plexus is considered by some to be the point of origin for leptomeningeal spread [14–17]. Others claim that choroid plexus involvement

is secondary to leptomeningeal metastasis elsewhere and does not represent the origin [18, 19]. Another plausible pathway is the perivascular space (Virchow-Robin) extending along the penetrating vessels [20, 21]. In addition, the subarachnoid space communicates with the perineural space of the nerve roots. These connections provide an accessible pathway through which tumor cells might reach the leptomeninges [22–25]. However, hematogenous spread through meningeal vessels is the most convincing theory for the dissemination of tumor into the subarachnoid space [26, 27].

In our institution, CSF cytology is a routine test for the initial staging and subsequent restaging of patients who have relapsed from leukemia and lymphoma. Once the diagnosis of leptomeningeal metastasis is established, the treatment is usually initiated immediately, without a CT scan. This group of patients is more apt to be detected and treated in the earlier stages of their leptomeningeal disease. Therefore, the percentages of positive CT scans in our patients with leukemia (15.8%) and lymphoma (16.9%) are significantly lower than in those with breast (41%) or lung (57%) carcinoma. In our series, the CSF was evaluated most often before a CT scan was obtained, and in general, the scan was requested for the detection of possible parenchymal lesions. On occasion the CSF cytologic examination was done because the CT findings were strongly suggestive of leptomeningeal metastasis.

Leptomeningeal metastasis is often associated with parenchymal neoplasms in the brain [28, 29]. The high incidence of parenchymal lesions on CT in association with findings indicative of leptomeningeal metastasis has not previously been emphasized in the literature [30]. Usually these lesions are irradiated or removed surgically, particularly if solitary and symptomatic. The CSF is rarely if ever looked at in metastatic parenchymal tumors. Given our data, CT evidence of parenchymal disease, without significant mass effect and with leptomeningeal disease, strongly indicates that a lumbar puncture be done. This may be extremely helpful in overall treatment.

The obliteration of the subarachnoid space, cisterns, and sulci can be appreciated on CT before infusion of contrast material. However, leptomeningeal metastasis is better dem-




Fig. 5.—Postcontrast CT scans immediately (A) and 1 hr (B) after intravenous injection. Leptomeningeal enhancement in sylvian fissures, quadrigeminal cistern, and along tentorium has decreased markedly on delayed scan.

onstrated on the immediate postcontrast scans (fig. 5). The most frequently observed abnormality is sulcal-cisternal enhancement. This finding may be diffuse or localized, and is more often observed in the basal cisterns, sylvian fissures, and the high-convexity cortical sulci. This may be because of the vascularity of the tumor and/or the leptomeningeal reaction to tumor infiltration. The latter may explain the persistence of enhancement after the supposed disappearance of neoplastic cells, as reflected by repeated negative CSF cytologic examinations after intrathecal chemotherapy.

Communicating hydrocephalus is the second most common abnormality from leptomeningeal metastasis. It is manifested by symmetric dilatation of the ventricular system, usually to a mild or moderate degree. It can occur early in the disease before treatment and persist after the CSF is cleared of tumor cells. Leptomeningeal metastasis impairs the absorption of CSF, which in turn leads to ventricular dilatation and increased intracranial pressure. Brain irradiation and intrathecal chemotherapy have not been documented to be the causes of communicating hydrocephalus. In the absence of meningitis, subarachnoid hemorrhage, and previous treatment by surgery, leptomeningeal metastasis is very likely the cause of communicating hydrocephalus in the cancer patient. Sometimes, repeated CSF examinations are required to confirm leptomeningeal spread.

Tentorial enhancement as a manifestation of leptomeningeal metastasis probably results from the same mechanisms as those seen with sulcal-cisternal enhancement. Since tentorial enhancement normally occurs in the postcontrast scan, it only becomes significant when the enhancement is over a widened area representing a thickened tentorium, and is irregular in configuration. This may be diffuse or localized. For these reasons, tentorial enhancement is not as sensitive an observation in the diagnosis of leptomeningeal metastasis.

Ependymal-subependymal enhancement in either a diffuse or nodular pattern without surrounding edema frequently results from the periventricular spread of leptomeningeal tumor. It can be seen with metastases from extracranial neoplasms as well as with certain primary intracranial tumors




Fig. 6.—Postcontrast CT scans with oat cell carcinoma of the lung. Grand mal seizures developed while receiving intravenous contrast material for spinal CT study. An earlier cranial CT scan was normal, and CSF examination was negative. Diffuse gyral enhancement in high convexity of both cerebral hemispheres.

such as pinealoblastomas and medulloblastomas, which are often associated with subarachnoid seeding. Ependymal-subependymal enhancement usually disappears in response to treatment. However, sulcal-cisternal and tentorial enhancement may persist after negative cytologic examination.

Subarachnoid hemorrhage [31, 32] may be manifested by increased attenuation in the cisterns and sulci on precontrast studies. Arterial spasm related to subarachnoid hemorrhage may be reflected in gyral enhancement mimicking sulcal enhancement on the postcontrast examination as a result of gray-matter hypoxia. There may also be associated communicating hydrocephalus. Cerebral arteriography may be necessary to establish the existence of arterial spasm. The clinical features and evaluation of the CSF should confirm the diagnosis.

Similar CT observations occur in meningeal inflammation from any etiology, particularly from granulomatous infection such as tuberculosis [33]. The enhancement seen after infusion of contrast material is on occasion virtually impossible to differentiate from leptomeningeal metastasis. Sometimes even the clinical presentation and CSF abnormalities such as elevated protein and depressed glucose levels may be confusing. CSF cytology and culture results frequently offer pertinent information in making the diagnosis.

Subacute infarction with gyral enhancement is another consideration in the differential diagnosis [34]. The associated edema with the resulting loss of cortical sulci and gyral enhancement may mimic the sulcal enhancement seen in leptomeningeal metastasis. However, the unilateral hemispheric involvement in a vascular distribution in conjunction with the clinical features should lead to a correct diagnosis.

On occasion, a CT scan obtained immediately after seizure [35, 36], particularly if it is a grand mal seizure, may show diffuse gyral enhancement (fig. 6).

In our experience, which agrees with previous reports [30, 37], the four major CT abnormalities seen in patients with leptomeningeal metastasis are sulcal-cisternal enhancement, ependymal-subependymal enhancement, widened irregular tentorial enhancement, and communicating hydrocephalus.

Communicating hydrocephalus in cancer patients should be considered secondary to leptomeningeal spread of tumor until proven otherwise. In some cases, repeated CSF cytologic examinations may be necessary to make a definitive diagnosis. In addition, because of the relatively high incidence of leptomeningeal spread, patients with parenchymal lesions exhibiting symptoms, signs, and/or CT abnormalities suggestive of leptomeningeal metastasis should undergo a lumbar puncture unless contraindicated by mass effect.

REFERENCES

1. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastasis from solid tumors: experiences with 90 patients. *Cancer* **1982**;49:759-772
2. Beerman WF. Meningeal carcinomatosis. *JAMA* **1912**;58:1437-1438
3. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. *Adv Neurol* **1978**;19:579-592
4. Bunn PA, Schein PS. Meningeal involvement in lymphoma. *N Engl J Med* **1974**;290:517
5. Bunn PA, Schein PS, Banks PM, DeVita VT. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. *Blood* **1976**;47:3-9
6. Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in the non-Hodgkins lymphomas. *Cancer* **1980**;45:545-552
7. Yap HY, Yap BS, Tashima CK, DiStefano A, Blumenschein GR. Meningeal carcinomatosis in breast cancer. *Cancer* **1978**;42:283-286
8. Nugent JL, Bunn PA, Matthews MJ, et al. CNS metastases in small cell bronchogenic carcinoma—increasing frequency and changing patterns with lengthening survival. *Cancer* **1979**;44:1885-1893
9. Kokkoris CP. Leptomeningeal carcinomatosis: how does cancer reach the pia-arachnoid? *Cancer* **1983**;51:154-160
10. Naylor B. The cytologic diagnosis of cerebrospinal fluid. *Acta Cytol (Baltimore)* **1964**;8:141-149
11. Gondos B, King EB. Cerebrospinal fluid cytology: diagnostic accuracy and comparison of different techniques. *Acta Cytol (Baltimore)* **1976**;20:542-547
12. Choi HH, Anderson PJ. Diagnostic cytology of cerebrospinal fluid by the cytocentrifuge method. *Am J Clin Pathol* **1979**;72:931-943
13. Olson M, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer: a clinical and pathologic study. *Arch Neurol* **1974**;30:122-137
14. Dinsdale HE, Taghavy A. Carcinomatosis of the meninges. *Can Med Assoc J* **1964**;90:505-512
15. Hermann DL, Conville CB. Pathogenesis of meningeal carcinomatosis. *Bull Los Angeles Neurol Soc* **1965**;30:107-117
16. Hamrick J, Mason-Hohl E. Carcinomatosis of the meninges without involvement of the parenchyma of the brain. *Ann West Med Surg* **1948**;2:375-376
17. Daum S, Foncin JF. Les tumeurs diffuses des leptomeninges. *Rev Neurol (Paris)* **1963**;108:597-611
18. Grain GO, Karr JF. Diffuse leptomeningeal carcinomatosis. *Neurology (NY)* **1955**;5:706-722
19. Gonzales-Vitale JC, Garcia-Bunuel R. Meningeal carcinomatosis. *Cancer* **1976**;37:2906-2911
20. Lewis NCD. An unusual manifestation of metastatic miliary carcinomatosis of the meninges. *Am J Psychiatry* **1925**;5:171-187
21. Stam FC. Leptomeningeal carcinosis. *Psychiatr Neurol Neurochir* **1960**;63:2-7
22. Uspenski E. On diffuse carcinomatous metastases in the nervous system. *J Neuropathol Exp Neurol* **1943**;2:103-110
23. Chen CJ. The perineural space of the peripheral nerve (thesis). Montreal, Quebec, Canada: McGill University, **1945**
24. Griffin JW, Thompson RW, Mitchinson MJ, de Kiewiet K, Welland FH. Lymphomatous leptomeningitis. *Am J Med* **1971**;51:200-208
25. Willis RA. *Pathology of tumors*, 4th ed. New York: Appleton-Century-Crofts, **1967**
26. Jacobs LL, Richland KJ. Carcinomatosis of the leptomeninges. *Bull Los Angeles Neurol Soc* **1951**;16:335-356
27. Fischer-Williams M, Bosanquet FD, Daniel PM. Carcinomatosis of the meninges. *Brain* **1955**;78:42-58
28. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in the cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. *Neurology (NY)* **1979**;29:1369-1375
29. Glass JP, Wertlake PT. Malignant cells in the cerebrospinal fluid and their clinical significance. In: Wood JH, *Neurobiology of cerebrospinal fluid 2*. New York: Plenum, **1983**:411-425
30. Ascherl GF, Hilal SK, Brisman R. Computed tomography of disseminated meningeal and ependymal malignant neoplasms. *Neurology (NY)* **1981**;3L:567-574
31. Liliequist B, Lindqvist M. Computer tomography in the evaluation of subarachnoid hemorrhage. *Acta Radiol [Diagn] (Stockh)* **1980**;21:327-331
32. Sobel D, Li FC, Norman D, Newton TH. Cisternal enhancement after subarachnoid hemorrhage. *AJNR* **1981**;2:549-552
33. Casselman ES, Hasso AN, Ashwal S, Schneider S. Computed tomography of tuberculous meningitis in infants and children. *J Comput Assist Tomogr* **1980**;4:211-216
34. Weisberg LA. Computed tomographic enhancement patterns in cerebral infarction. *Arch Neurol* **1980**;37:21-24
35. Rumack CM, Guggenheim MA, Fasules JW, Burdick D. Transient positive postictal computed tomographic scan. *J Pediatr* **1980**;97:263-264
36. Dillon W, Brant-Zawadzki M, Sherry RG. Transient computed tomographic abnormalities after focal seizures. *AJNR* **1984**;5:107-109
37. Enzmann DR, Krikorian CY, Hayward R. Computed tomography in leptomeningeal spread in tumor. *J Comput Assist Tomogr* **1978**;2:448-455